share_log

君聖泰醫藥-B：HTD1801治療代謝異常性脂肪性肝炎(MASH) IIb期的臨床試驗完成患者入組

HIGHTIDE-B: COMPLETION OF PATIENT ENROLLMENT IN PHASE IIb CLINICAL TRIAL EVALUATING HTD1801 IN MASH

HKEX ·  Apr 3 05:56

Summary by Moomoo AI

君聖泰醫藥宣布其自主研發的HTD1801治療代謝異常性脂肪性肝炎的IIb期臨床試驗已完成患者入組。該試驗針對伴有2型糖尿病或糖尿病前期的患者，並於2022年12月開始，在美國、香港及中國大陸共入組218名患者。HTD1801獲美國FDA授予快速通道資格，旨在加速治療代謝異常性脂肪性肝炎的藥物開發。君聖泰醫藥專注於開發多功能多靶點療法，目前持有全球知識產權，並推進多項中後期臨床試驗。公司提醒股東及潛在投資者，HTD1801的開發成功與否仍存在不確定性。
君聖泰醫藥宣布其自主研發的HTD1801治療代謝異常性脂肪性肝炎的IIb期臨床試驗已完成患者入組。該試驗針對伴有2型糖尿病或糖尿病前期的患者，並於2022年12月開始，在美國、香港及中國大陸共入組218名患者。HTD1801獲美國FDA授予快速通道資格，旨在加速治療代謝異常性脂肪性肝炎的藥物開發。君聖泰醫藥專注於開發多功能多靶點療法，目前持有全球知識產權，並推進多項中後期臨床試驗。公司提醒股東及潛在投資者，HTD1801的開發成功與否仍存在不確定性。
Jun Shengtai Pharmaceuticals announced that its self-developed HTD1801 Phase IIb clinical trial for the treatment of metabolic abnormal fatty hepatitis has been completed. The trial, in patients with type 2 diabetes or prediabetes, began in December 2022 and enrolled 218 patients in the United States, Hong Kong and Mainland China. HTD1801 has been granted fast-track status by the U.S. FDA to accelerate drug development for the treatment of metabolic abnormal fatty hepatitis. JunShengtai Pharmaceuticals focuses on the development of multifunctional multi-target therapies, currently holds global intellectual property rights and promotes several mid-term and late-stage clinical trials. The Company reminds shareholders and potential investors that there is still uncertainty about the success of HTD1801's development.
Jun Shengtai Pharmaceuticals announced that its self-developed HTD1801 Phase IIb clinical trial for the treatment of metabolic abnormal fatty hepatitis has been completed. The trial, in patients with type 2 diabetes or prediabetes, began in December 2022 and enrolled 218 patients in the United States, Hong Kong and Mainland China. HTD1801 has been granted fast-track status by the U.S. FDA to accelerate drug development for the treatment of metabolic abnormal fatty hepatitis. JunShengtai Pharmaceuticals focuses on the development of multifunctional multi-target therapies, currently holds global intellectual property rights and promotes several mid-term and late-stage clinical trials. The Company reminds shareholders and potential investors that there is still uncertainty about the success of HTD1801's development.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated